The knockdown of HER2 restored sensitivity to EGFR TKIs in H1781 lung cancer cells which have the G776YVMA mutation, suggesting that inhibition of HER2 may prove a promising target to bypass EGFR TKI resistance [68]. This evidence concerns the gene ERBB2 and lung carcinoma.